Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

pan-PIM Kinase Inhibitor NVP-LGB-321

Known as: NVP-LGB-321, PIM Inhibitor NVP-LGB-321, PIM Kinase Inhibitor NVP-LGB-321 
An orally available, small molecule and selective ATP-competitive pan-inhibitor of proviral integration sites for Moloney murine leukemia virus (PIM… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
UNLABELLED Patient stratification biomarkers that enable the translation of cancer genetic knowledge into clinical use are… Expand
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Oncogene activation has been shown to generate replication-born DNA damage, also known as replicative stress. The primary… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Aberrant genetic alternations in human gliomas, such as amplification of epidermal growth factor receptor, mutation and/or… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Phosphatidylinositol-3-kinase (PI3K) pathway deregulation is a common event in human cancer, either through inactivation of the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
We describe the biological properties of NVP-AUY922, a novel resorcinylic isoxazole amide heat shock protein 90 (HSP90) inhibitor… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
The role of NMDA receptors in the induction of long-term potentiation (LTP) and long-term depression (LTD) is well established… Expand
Is this relevant?
Highly Cited
2006
Highly Cited
2006
NVP-AAM077 was kindly provided by Dr. Yves Auberson (Novartis, Basel, Switzerland). We thank Philippe Ascher and Boris Barbour… Expand
  • figure 1
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. The synthesis and… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Histone deacetylase (HDAC) inhibitors are emerging as a promising new treatment strategy in hematologic malignancies. Here we… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
OBJECTIVE Glucagon-like peptide-1 (GLP-1) has been proposed as a new treatment modality for type 2 diabetes. To circumvent the… Expand
  • figure 1—24
  • figure 2
  • table 1
  • table 2
Is this relevant?